QLT (NASDAQ:QLTI) : Currently there are 2 street experts covering QLT (NASDAQ:QLTI) stock. The most bullish and bearish price target for the stock is $5 and $3 respectively for the short term. The average price target of all the analysts comes to $3.63. The estimated standard deviation from the target is $1.24.
QLT Inc. has lost 0.7% in the last five trading days and dropped 5.96% in the last 4 weeks. QLT Inc. has dropped 27.18% during the last 3-month period . Year-to-Date the stock performance stands at -46.62%.
QLT (NASDAQ:QLTI) has an average broker rating of 2, which is interpreted as a Buy, as rated by 2 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.
QLT (NASDAQ:QLTI): The stock was completely flat for the day, closing at $1.42 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $1.40, the stock touched an intraday high of $1.44 and a low of $1.38. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.42. The total trading volume on Thursday was 3,183,408.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Qlt Inc/Bc, Aryeh Jason, had purchased 18,400 shares in a transaction dated on December 29, 2015. The transaction was executed at $2.49 per share with total amount equaling $45,816.
QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of ocular products. QLT is engaged in the development of QLT091001 for the treatment of Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, a biochemical component of the visual retinoid cycle, and is used for the treatment of certain age-related and inherited retinal degenerative diseases. The Companys QLT091001 product candidate has completed a Phase Ib retreatment study for the treatment of LCA and RP, a Phase Ib study for the treatment of RP with autosomal dominant mutation in retinal pigment epithelium protein 65 (RPE65) and a Phase IIa study for the treatment of impaired dark adaptation (IDA). QLT091001 has received orphan drug designations for the treatment of LCA and RP by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).